Literature DB >> 18378537

Commentary: Novel therapies for cancer: why dirty might be better.

Tito Fojo1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18378537     DOI： 10.1634/theoncologist.2007-0090

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  20 in total

Review 1.  Cancer drug development: The missing links.

Authors:  Ajaikumar B Kunnumakkara; Devivasha Bordoloi; Bethsebie Lalduhsaki Sailo; Nand Kishor Roy; Krishan Kumar Thakur; Kishore Banik; Mehdi Shakibaei; Subash C Gupta; Bharat B Aggarwal
Journal:  Exp Biol Med (Maywood)       Date:  2019-04-08

Review 2.  Mechanisms of drug resistance in kinases.

Authors:  Rina Barouch-Bentov; Karsten Sauer
Journal:  Expert Opin Investig Drugs       Date:  2011-02       Impact factor: 6.206

3.  Kinase inhibition-related adverse events predicted from in vitro kinome and clinical trial data.

Authors:  Xinan Yang; Yong Huang; Matthew Crowson; Jianrong Li; Michael L Maitland; Yves A Lussier
Journal:  J Biomed Inform       Date:  2010-05-01       Impact factor: 6.317

4.  Inhibition of glutathione peroxidase mediates the collateral sensitivity of multidrug-resistant cells to tiopronin.

Authors:  Matthew D Hall; Travis S Marshall; Alexandra D T Kwit; Lisa M Miller Jenkins; Andrés E Dulcey; James P Madigan; Kristen M Pluchino; Andrew S Goldsborough; Kyle R Brimacombe; Gary L Griffiths; Michael M Gottesman
Journal:  J Biol Chem       Date:  2014-06-14       Impact factor: 5.157

Review 5.  Redox-directed cancer therapeutics: molecular mechanisms and opportunities.

Authors:  Georg T Wondrak
Journal:  Antioxid Redox Signal       Date:  2009-12       Impact factor: 8.401

Review 6.  Combined therapies for cancer: a review of EGFR-targeted monotherapy and combination treatment with other drugs.

Authors:  Beata Zahorowska; Philip J Crowe; Jia-Lin Yang
Journal:  J Cancer Res Clin Oncol       Date:  2009-06-17       Impact factor: 4.553

7.  Monocarbonyl curcumin analogues: heterocyclic pleiotropic kinase inhibitors that mediate anticancer properties.

Authors:  Andrew Brown; Qi Shi; Terry W Moore; Younghyoun Yoon; Andrew Prussia; Clinton Maddox; Dennis C Liotta; Hyunsuk Shim; James P Snyder
Journal:  J Med Chem       Date:  2013-04-23       Impact factor: 7.446

8.  Association between treatment toxicity and outcomes in oncology clinical trials.

Authors:  M V Abola; V Prasad; A B Jena
Journal:  Ann Oncol       Date:  2014-09-05       Impact factor: 32.976

9.  Advances in cancer therapeutics.

Authors:  A Sparreboom; J Verweij
Journal:  Clin Pharmacol Ther       Date:  2009-02       Impact factor: 6.875

Review 10.  Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?

Authors:  Kristy J Gotink; Henk M W Verheul
Journal:  Angiogenesis       Date:  2009-12-11       Impact factor: 9.596
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.